Accordingly, ZEB1 upregulation in EpCAMlo colon cancer cells is invariably accompanied by ESRP1/2 downregulation, and ZEB1hi/ESRP1lo colon cancers, predominantly belonging to the mesenchymal CMS4 subgroup, have a significantly worse survival outcome when compared with ZEB1lo/ESRP1hi patients. This evidence concerns the gene ZEB1 and colonic neoplasm.